137 related articles for article (PubMed ID: 16096428)
1. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
[TBL] [Abstract][Full Text] [Related]
2. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
[TBL] [Abstract][Full Text] [Related]
3. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
8. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Ozawa Y; Kusano K; Owa T; Yokoi A; Asada M; Yoshimatsu K
Cancer Chemother Pharmacol; 2012 May; 69(5):1353-62. PubMed ID: 22349812
[TBL] [Abstract][Full Text] [Related]
10. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
11. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
13. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
Wildiers H; Ahmed B; Guetens G; De Boeck G; de Bruijn EA; Landuyt W; van Oosterom AT
Eur J Cancer; 2004 Jan; 40(2):284-90. PubMed ID: 14728944
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
[TBL] [Abstract][Full Text] [Related]
20. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
